Overview
Spinal Cord Stimulation (SCS) is a newly emerged neuromodulation technique in recent years. It is now a mature technique in the treatment of chronic pain and is generally accepted by patients because of its non-destructive and reversible nature, few complications, no side effects, and avoidance of unnecessary surgical procedures. Combining the results of previous studies and the group's previous research, this study first proposes an innovative treatment protocol for multiple system atrophy with SCS. We intend to conduct a prospective single-center open clinical trial to evaluate the improvement of orthostatic hypotension, urinary retention, sleep disturbance, dysarthria, and dysphagia in multiple system atrophy (MSA) patients before and after SCS treatment, and shed new light on the treatment for MSA.
Eligibility
Inclusion Criteria:
- Meeting possible or probable multiple system atrophy (MSA) criteria according to the 2008 second consensus statement on the diagnosis of MSA.
- Citizens of the People's Republic of China, aged >18 years and <80 years.
- The presence of significant symptoms of dysarthria, dysphagia, orthostatic hypotension or urinary retension in patients with MSA.
- Maintaining medication during the study period.
- Good compliance, signed written informed consent, and consent to surgical treatment of spinal cord stimulation (SCS).
Exclusion Criteria:
- Patients with severe neuropsychiatric disorders or a history of severe neuropsychiatric disorders.
- Patients with significant cognitive impairment (Mini-Mental State Exam < 24) or inability to complete the questionnaire independently.
- Presence of anatomical abnormalities or other lesions of the spine that interfere with electrode implantation
- Dysarthria, swallowing difficulties, orthostatic hypotension from other causes not related to MSA.
- Critically ill or unstable vital signs.
- Other conditions that in the opinion of the investigator make them unsuitable for participation in this study.